4//SEC Filing
Neufeld Leah R 4
Accession 0001628280-24-024939
CIK 0001790340other
Filed
May 22, 8:00 PM ET
Accepted
May 23, 4:14 PM ET
Size
17.4 KB
Accession
0001628280-24-024939
Insider Transaction Report
Form 4
Immuneering CorpIMRX
Neufeld Leah R
CHIEF PEOPLE OFFICER
Transactions
- Disposition to Issuer
Stock Option
2024-05-21−105,000→ 0 totalExercise: $4.25Exp: 2033-02-15→ Class A Common Stock (105,000 underlying) - Disposition to Issuer
Stock Option
2024-05-21−60,500→ 0 totalExercise: $6.09Exp: 2034-02-08→ Class A Common Stock (60,500 underlying) - Award
Stock Option
2024-05-21+105,000→ 105,000 totalExercise: $3.01Exp: 2033-02-15→ Class A Common Stock (105,000 underlying) - Award
Stock Option
2024-05-21+60,500→ 60,500 totalExercise: $3.01Exp: 2034-02-08→ Class A Common Stock (60,500 underlying) - Disposition to Issuer
Stock Option
2024-05-21−88,600→ 0 totalExercise: $13.85Exp: 2032-10-31→ Class A Common Stock (88,600 underlying) - Award
Stock Option
2024-05-21+88,600→ 88,600 totalExercise: $3.01Exp: 2032-10-31→ Class A Common Stock (88,600 underlying)
Footnotes (4)
- [F1]On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]The option vests and becomes exercisable as to 25% of the underlying shares on October 17, 2023 and then in equal monthly installments over the subsequent three years, subject to Ms. Neufeld's continued employment through each applicable vesting date.
- [F3]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.
- [F4]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.
Documents
Issuer
Immuneering Corp
CIK 0001790340
Entity typeother
Related Parties
1- filerCIK 0001950673
Filing Metadata
- Form type
- 4
- Filed
- May 22, 8:00 PM ET
- Accepted
- May 23, 4:14 PM ET
- Size
- 17.4 KB